FAQ

CEOP-IMVP-Dexa regimen

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2015
0119912015

Related topics

Related topics

9 relations

Broader (9)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDexamethasoneEpirubicin
(More)

Related mentions per year

Related mentions per year

1945-2018
19401960198020002020
CEOP-IMVP-Dexa regimen
Cyclophosphamide
Dexamethasone
Methotrexate
prednisolone
Etoposide

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A HHV-8 positive, HIV negative multicentric Castleman disease treated with R-CEOP chemotherapy and valganciclovir combination.
Multicentric Castleman disease (MCD) is a lymphoproliferative disorder characterized by systemic symptoms like recurrent… (More)
Is this relevant?
2015
2015
Dysfunctional neobladder causing pulmonary toxicity after combination chemotherapy for lymphoma.
A 75-year-old man with transitional cell bladder carcinoma status post cystoprostatectomy with neobladder creation from the… (More)
  • figure 1
Is this relevant?
2012
2012
Prognostic value of platelet count in diffuse large B-cell lymphoma.
BACKGROUND Besides International Prognostic Index, many parameters have proven prognostic significance in aggressive lymphoma… (More)
Is this relevant?
2009
2009
Dose-dense therapy improves survival in aggressive non-Hodgkin’s lymphoma
This study aimed to determine whether dose-dense therapy improves 3-year survival over the standard therapy for untreated… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
2004
2004
Phase II Study of Cyclophosphamide, Epirubicin, Vincristine, Prednisone, and Etoposide (CEOP-E) for Aggressive Non-Hodgkin's Lymphoma
The main objectives of the current study were to evaluate the efficacy and safety of a CEOP-E regimen for patients with… (More)
  • table 2
  • table 1
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Review
1998
Review
1998
Chemotherapy in patients with acquired immunodeficiency virus syndrome associated with non-Hodgkin's lymphoma.
We retrospectively analyzed our chemotherapy results in patients with the Acquired Immunodeficiency Virus syndrome (AIDS) and… (More)
Is this relevant?
1997
1997
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi…
Primary end point of this trial was to reduce neutropenic infections during the treatment of aggressive NHL with CEOP/IMVP-Dexa… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
1996
1996
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
PURPOSE This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter… (More)
Is this relevant?
1995
1995
Malabsorption associated with a high-grade-malignant non-Hodgkin's lymphoma, alpha-heavy-chain disease and immunoproliferative small intestinal disease.
We report on a 28 year old Turkish woman, who was admitted to our hospital with the symptoms of malabsorption and protein-loosing… (More)
Is this relevant?
1991
1991
Toxicity and preliminary results with a new eight-drug regimen (CEOP-IMVP-DEXA) in the treatment of aggressive lymphomas.
A combination of two non-cross-resistant regimens, CEOP and IMVP-Dexa given every 4 weeks, three to six times according to… (More)
Is this relevant?